The Expanding Pill

Stone, Andy
October 2005
Forbes Asia;10/17/2005, Vol. 1 Issue 5, p64
The article reports on the technique developed by pharmaceutical firm Depomed for keeping drugs in the stomach up to 12 hours before they fully dissolve. Its ingredient is polyethylene oxide, the same low-cost polymer that fluffs up toothpaste and soft-service ice cream. Depomed received U.S. Food & Drug Administration approval for Proquin XR, a gastric-retentive version of ciprofloxacin that expands to the size of a nickel once it hits the stomach.


Related Articles

  • AAN 2011: recent FDA approvals for niche indications provide a positive tone.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p13 

    The article focuses on the U.S. Food and Drugs Administration (FDA) approved drugs for niche neurological indications highlighted at the 63rd American Academy of Neurology Annual Meeting (AAN) on April 9-16, 2011 in Honolulu, Hawaii. FDA has approved Nuedexta, a drug for treating pseudobulbar...

  • Depomed's Gralise Gets PHN Nod; Now Who Will Market? Boggs, Jennifer // BioWorld Today;2/1/2011, Vol. 22 Issue 21, p2 

    The article reports on a 34.3 percent increase in shares of Depomed Inc. following the approval by the U.S. Food and Drug Administration (FDA) of the company's once-daily tablet formulation of gabapentin, branded Gralise, in postherpetic neuralgia. Gralise's orphan designation and the company's...

  • CLINIC ROUNDUP.  // BioWorld Today;3/13/2007, Vol. 18 Issue 49, p5 

    The article offers news related to the biopharmaceutical industry. Chemokine Therapeutics Corp. has successfully completed the dose-escalation portion of its Phase Ib/II trial of its anticancer drug. A new drug application was submitted by Depomed Inc. with the Food and Drug Administration for...

  • Parkinson's Update.  // PharmaWatch: CNS;Mar2012, Vol. 11 Issue 3, p9 

    The article offers world news briefs related to drugs for Parkinson's disease (PD). Otsuka Pharmaceutical Co. Ltd. has submitted a manufacturing and marketing approval application in Japan for its dopamine agonist transdermal patch, Rotigotine patch. It is announced that Santhera Pharmaceuticals...

  • CNS News Round-Up.  // PharmaWatch: CNS;Mar2012, Vol. 11 Issue 3, p2 

    The article offers U.S. news briefs related to pharmaceutical industry. Depomed Inc. has announced the initiation of its Phase II clinical trial of DM-1992 carbidopa/levodopa formulation for patients with advanced Parkinson's disease. Biogen Idec Inc. and Elan Corp. PLC has commenced its global...

  • Would Depomed Drug OK Change the PHN Dynamic? Young, Donna // BioWorld Today;4/1/2010, Vol. 21 Issue 62, p1 

    This article reports on the optimism expressed by Depomed Inc. over news that their partner Abbott filed a new drug application for DM-1796, an extended-release formulation of gabapentin. The new drug is indicated for people with postherpetic neuralgia. On March 31, 2010, Depomed shares dropped...

  • FDA OKs extended-release ciprofloxacin.  // Drug Topics;6/6/2005, Vol. 149 Issue 11, p10 

    This article announces the approval of Ciprofloxacin, once-daily, extended-release formulation of ciprofloxacin, for the treatment of uncomplicated urinary tract infections.

  • Generic Form Of Injectable Cipro Gets Green Light. Scholz, Mary; Bauer, Jeff // RN;Oct2006, Vol. 69 Issue 10, p57 

    The article reports on the approval of a generic version of the antibiotic ciprofloxacin injection (Cipro IV Injection) by the U.S. Food and Drug Administration. Ciprofloxacin is used to treat many bacterial infections, such as lower respiratory tract infections, urinary tract infections, bone...

  • CNS News Round-Up.  // PharmaWatch: Monthly Review;May2010, Vol. 9 Issue 5, p14 

    The article offers news briefs related to the treatment of central nervous system diseases. The U.S. Food and Drug Administration (FDA) has given approval to generics firm Actavis Group hf. to market Alprazolam orally disintegrating tablets. FDA has also approved an abbreviated New Drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics